<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02933138</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL16_0636</org_study_id>
    <nct_id>NCT02933138</nct_id>
  </id_info>
  <brief_title>Plasma Triglyceride Lipolysis in Multifactorial Chylomicronemia</brief_title>
  <official_title>Systematic Study of Post Herapin Lipoprotein Lipase Activity and Lipoprotein Remodelling in Multifactorial Chylomicronemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <brief_summary>
    <textblock>
      Purpose: The mechanism of most of the multifactorial chylomicronemia (MCM) remains elusive.
      In order to decipher the mechanisms involved in the occurrence of this disease, plasma TG
      lipolysis characteristics will be monitored for 60 minutes after heparin injection instead of
      the 10 minutes gold standard, in a large group of genotyped MCM patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: The mechanism of most of the multifactorial chylomicronemia (MCM) remains elusive.
      In order to decipher the mechanisms involved in the occurrence of this disease, plasma TG
      lipolysis characteristics will be monitored for 60 minutes after heparin injection instead of
      the 10 minutes gold standard, in a large group of genotyped MCM patients.

      Method: LPL, APOC2, APOA5, GPIHB1and APOE genotypes will be determined for each patient.
      Basal lipid profiles including Apo B, CII, CIII, and lipoprotein lipase (LPL) concentration
      will be measured in 62 MCM patients, in addition to LPL activity (PHLA) T0, T10 T30 T60
      minutes, Assessment of TG chylomicron decrease Study of lipoprotein remodelling by agarose
      gel electrophoresis.

      Hypothesis To confirm the preliminary finding of high LPL activity in multifactorial
      chylomicronemia To explore the interest of a longer assessment of LPL activity following
      heparin injection. To establish if specific phenotypes could be identified among MCM patient
      supporting the hypothesis of different mechanisms involved (ie overproduction or defect in
      hepatic clearance)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lipoprotein Lipase concentration</measure>
    <time_frame>60 minutes after heparin injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Basal lipid profiles</measure>
    <time_frame>maximum 60 min before heparin injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipoprotein electrophoresis</measure>
    <time_frame>maximum 60 minutes after heparin injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total triglycerides decrease</measure>
    <time_frame>maximum 60 minutes after heparin injection</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">62</enrollment>
  <condition>Hyperlipoproteinemia</condition>
  <arm_group>
    <arm_group_label>Multifactorial Chylomicronemia</arm_group_label>
    <description>no intervention, phenotypic and genotypic study</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      post-heparin EDTA plasma ADN
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patient with a documented history of MCM (Plasma TG concentration (TG) &gt; 15 mmol/l or
        familial history of hypertriglyceridemia with TG &gt;10 mmol/l) who had no contraindication
        for a single heparin injection for ex vivo LPL activity assessment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient with a documented history of MCM (Plasma TG concentration (TG) &gt; 15 mmol/l or
             familial history of hypertriglyceridemia with TG &gt;10 mmol/l)

          -  no contraindication for a single heparin injection for ex vivo LPL activity assessment

        Exclusion Criteria:

          -  patients carriers of homozygous or compound heterozygous mutations on LPL, GPIHBP1,
             APOA5, APOC2 or APOE genes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2016</study_first_submitted>
  <study_first_submitted_qc>October 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2016</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lipoprotein Lipase</keyword>
  <keyword>Hypertriglyceridemia</keyword>
  <keyword>Triglycerides</keyword>
  <keyword>Lipolysis</keyword>
  <keyword>Multifactorial Chylomicronemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

